Arrowhead瞄准肥胖市场,公布双基因沉默药物早期数据。
Arrowhead takes aim at obesity market with early data on dual gene silencing assets
生物技术与制药领域的最新动态
Arrowhead takes aim at obesity market with early data on dual gene silencing assets
In Structure licensing deal, Roche commits $100M to shore up GLP-1 position
Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator
Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact
Amgen to acquire Dark Blue Therapeutics for up to $840M
Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treat - PharmiWeb.com
From Young Researcher Award Finalist to International Collaborator: Two Visits to Promega
In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech
Illumina launches cloud-based platform for multiomic data analysis - Investing.com
Roche's patent deal with Structure; AstraZeneca reports lupus data
Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal
Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference - BioSpace
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis - Illumina
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis - Illumina
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis - PR Newswire
Bottleneck size drives the evolution of cooperative traits in an aggregative multicellular myxobacterium
A light-entrained clock mechanism in a hydrozoan jellyfish synchronizes evening gamete release
Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago - Nasdaq
CDC, following Trump’s orders, weakens US stance on childhood vaccinations